These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 9367417)
1. Elevated soluble Fas/APO-1 (CD95) levels in silicosis patients without clinical symptoms of autoimmune diseases or malignant tumours. Tomokuni A; Aikoh T; Matsuki T; Isozaki Y; Otsuki T; Kita S; Ueki H; Kusaka M; Kishimoto T; Ueki A Clin Exp Immunol; 1997 Nov; 110(2):303-9. PubMed ID: 9367417 [TBL] [Abstract][Full Text] [Related]
2. Serum levels of soluble Fas ligand in patients with silicosis. Tomokuni A; Otsuki T; Isozaki Y; Kita S; Ueki H; Kusaka M; Kishimoto T; Ueki A Clin Exp Immunol; 1999 Dec; 118(3):441-4. PubMed ID: 10594565 [TBL] [Abstract][Full Text] [Related]
3. Serum levels of soluble Fas/APO-1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases. Jodo S; Kobayashi S; Kayagaki N; Ogura N; Feng Y; Amasaki Y; Fujisaku A; Azuma M; Yagita H; Okumura K; Koike T Clin Exp Immunol; 1997 Jan; 107(1):89-95. PubMed ID: 9010262 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of cases with silicosis using the parameters related to Fas-mediated apoptosis. Otsuki T; Ichihara K; Tomokuni A; Sakaguchi H; Aikoh T; Matsuki T; Isozaki Y; Hyodoh F; Kusaka M; Kita S; Ueki A Int J Mol Med; 1999 Oct; 4(4):407-11. PubMed ID: 10493983 [TBL] [Abstract][Full Text] [Related]
5. [Levels and clinic significance of serum soluble Fas and soluble Fas ligand in coal workers' pneumoconiosis]. Yuan BJ; Liu ZZ; Ding XR; Zou JM Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2006 Feb; 24(2):96-8. PubMed ID: 16600114 [TBL] [Abstract][Full Text] [Related]
6. Lack of correlation between serum soluble Fas/APO-1 levels and autoimmune disease. Goel N; Ulrich DT; St Clair EW; Fleming JA; Lynch DH; Seldin MF Arthritis Rheum; 1995 Dec; 38(12):1738-43. PubMed ID: 8849345 [TBL] [Abstract][Full Text] [Related]
7. Serum sFAS levels are elevated in ANCA-positive vasculitis compared with other autoimmune diseases. Christensson M; Pettersson E; Eneslätt K; Christensson B; Bratt J; Rantapää-Dahlqvist S; Sundqvist KG J Clin Immunol; 2002 Jul; 22(4):220-7. PubMed ID: 12148596 [TBL] [Abstract][Full Text] [Related]
8. [Fas-Fas ligand system in silicosis patients]. Ueki A Nihon Eiseigaku Zasshi; 2000 Jul; 55(2):474-80. PubMed ID: 10981180 [TBL] [Abstract][Full Text] [Related]
17. Membrane and soluble forms of Fas (CD95) in peripheral blood lymphocytes and in serum from burns patients. Lebedev MJ; Ptitsina JS; Vilkov SA; Korablev SB; Novikov VV Burns; 2001 Nov; 27(7):669-73. PubMed ID: 11600245 [TBL] [Abstract][Full Text] [Related]
18. Correlation between serum concentrations of soluble Fas (CD95/Apo-1) and IL-18 in patients with systemic lupus erythematosus. Sahebari M; Rezaieyazdi Z; Nakhjavani MJ; Hatef M; Mahmoudi M; Akhlaghi S Rheumatol Int; 2012 Mar; 32(3):601-6. PubMed ID: 21120501 [TBL] [Abstract][Full Text] [Related]
19. Serum elevations of soluble Fas (CD95/apo-I) concur in deregulating T cell apoptosis during active lupus disease. Silvestris F; Williams RC; Calvani N; Grinello D; Tucci M; Cafforio P; Dammacco F Clin Exp Med; 2002 May; 2(1):13-27. PubMed ID: 12049185 [TBL] [Abstract][Full Text] [Related]
20. Do elevated levels of serum-soluble fas contribute to the persistence of activated lymphocytes in systemic lupus erythematosus? Bijl M; van Lopik T; Limburg PC; Spronk PE; Jaegers SM; Aarden LA; Smeenk RJ; Kallenberg GG J Autoimmun; 1998 Oct; 11(5):457-63. PubMed ID: 9802929 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]